CD33 and acute myeloid leukemia: An AML preclinical trial consisting of a therapy that combines azacytidine and gemtuzumab ozogamicin (GO) aimed to enhance the cytotoxicity of the CD33 antibody against AML blasts through epigenetic modifications of PTPN6 (Medeiros et al., 2018).